In this minisode, Ryan is joined by Vynamic’s Brian Schachter to discuss a few recent newsworthy items including: the Medicare reimbursement for biosimilars (00:32), 2023 Medicare Advantage Star Ratings and overall sentiment of the US Healthcare system (03:51), drug price increases outpacing inflation (10:18), and Mark Cuban’s Cost Plus Drug Company partnering with Capital Blue Cross (11:48).
Podcast Tags: healthcare, healthcare news, life sciences, Inflation Reduction Act, biosimilars, Medicare, , drug pricing, healthcare access, Mark Cuban, Capital Blue Cross
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at
Mindy McGrath, Healthcare Industry Advisor
Ryan Hummel, Executive and Head of Provider Sector
Brian Schachter, Director
Vynamic, an Inizio Advisory company, is a leading management consulting partner to global health organizations across Life Sciences, Health Services, and Health Technology. Founded and headquartered in Philadelphia, Vynamic has offices in Boston, Durham NC, and London. Our purpose is simple: We believe there is a better way. We are passionate about shaping the future of health, and for more than 20 years we’ve helped clients transform by connecting strategy to action.
Through a structured, yet flexible delivery model, our accomplished leaders work as an extension of client teams, enabling growth, performance, and culture. Vynamic has been recognized by organizations like Great Place to Work and Business Culture Awards for being leaders and innovators in consulting, company culture, and health. Visit Vynamic.com to discover how we can help transform your
organization or your career.